Liver transplantation for hepatocellular carcinoma: Historical evolution

Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT...

Full description

Bibliographic Details
Main Authors: Ince, V, Sahin, TT, Akbulut, S, Yilmaz, S
Language:unknown
Published: 2022
Subjects:
Online Access:http://hdl.handle.net/11616/86119
id ftinonuuniv:oai:abakus.inonu.edu.tr:11616/86119
record_format openpolar
spelling ftinonuuniv:oai:abakus.inonu.edu.tr:11616/86119 2023-05-15T18:11:21+02:00 Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria Ince, V Sahin, TT Akbulut, S Yilmaz, S 2022 http://hdl.handle.net/11616/86119 unknown http://hdl.handle.net/11616/86119 WORLD JOURNAL OF CLINICAL CASES 2022 ftinonuuniv 2023-01-05T18:01:41Z Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians. C1 [Ince, Volkan; Sahin, Tevfik Tolga; Akbulut, Sami; Yilmaz, Sezai] Inonu Univ, Surg & Liver Transplant Inst, Fac Med, TR-44280 Malatya, Turkey. [Akbulut, Sami] Inonu Univ, Biostat & Med Informat, Fac Med, TR-44280 Malatya, Turkey. [Akbulut, Sami] Inonu Univ, Surg & Liver Transplant Inst, Fac Med, Elazig Yolu 10 Km, TR-44280 Malatya, Turkey. C3 Inonu University; Inonu University; Inonu University Other/Unknown Material sami Unknown
institution Open Polar
collection Unknown
op_collection_id ftinonuuniv
language unknown
description Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians. C1 [Ince, Volkan; Sahin, Tevfik Tolga; Akbulut, Sami; Yilmaz, Sezai] Inonu Univ, Surg & Liver Transplant Inst, Fac Med, TR-44280 Malatya, Turkey. [Akbulut, Sami] Inonu Univ, Biostat & Med Informat, Fac Med, TR-44280 Malatya, Turkey. [Akbulut, Sami] Inonu Univ, Surg & Liver Transplant Inst, Fac Med, Elazig Yolu 10 Km, TR-44280 Malatya, Turkey. C3 Inonu University; Inonu University; Inonu University
author Ince, V
Sahin, TT
Akbulut, S
Yilmaz, S
spellingShingle Ince, V
Sahin, TT
Akbulut, S
Yilmaz, S
Liver transplantation for hepatocellular carcinoma: Historical evolution
author_facet Ince, V
Sahin, TT
Akbulut, S
Yilmaz, S
author_sort Ince, V
title Liver transplantation for hepatocellular carcinoma: Historical evolution
title_short Liver transplantation for hepatocellular carcinoma: Historical evolution
title_full Liver transplantation for hepatocellular carcinoma: Historical evolution
title_fullStr Liver transplantation for hepatocellular carcinoma: Historical evolution
title_full_unstemmed Liver transplantation for hepatocellular carcinoma: Historical evolution
title_sort liver transplantation for hepatocellular carcinoma: historical evolution
publishDate 2022
url http://hdl.handle.net/11616/86119
genre sami
genre_facet sami
op_source WORLD JOURNAL OF CLINICAL CASES
op_relation http://hdl.handle.net/11616/86119
_version_ 1766184029062692864